Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

ATI US Equity

Ati IncMaterials · Steel Pipe & Tubes · CIK 1018963 · FY ends Dec 28
$226.46
-5.32 (-2.30%)
USD · as of 2026-08-18 · marketstack
2 registered studies · 2 active

Studies where ATI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

2 observational

Held by 23 tracked-famous managers (Qube Research & Technologies Ltd, AQR CAPITAL MANAGEMENT LLC, JANE STREET GROUP, LLC, Point72 Asset Management, L.P., VIKING GLOBAL INVESTORS LP, +18 more) · FINRA short interest 2.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 9 sells · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionReadout inUpdated
ATI Evidence-based Guide Investigating Medical and Preventative ServicesNCT04050319observationalNumerical Rating Scale (NRS)Active, not recruitingDiagnostic test: Screening and diagnosis if injuredSport Medicine550,0002029-04-23in 978 d2026-05-04
ATI Evidence-based Guide Investigating Clinical ServicesNCT02285868observationalChange in functional statusActive, not recruitingPrimary Body Region (Arranged Most Common to Least), Lumbar/SI, Knee, Shoulder, Cervical/Thoracic, Foot/Ankle, Hip, Elbow, Neurological, Vestibular, Pelvic Floor, TMJ, Fibromyalgia, Headaches, Lymphedema4,000,0002029-02-24in 920 d2026-03-05

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19